PMID- 23500519
OWN - NLM
STAT- MEDLINE
DCOM- 20140819
LR  - 20130517
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
VI  - 43
DP  - 2013 May
TI  - In vivo characterization of the effects of ghrelin on the modulation of acute 
      pain at the supraspinal level in mice.
PG  - 76-82
LID - S0196-9781(13)00078-8 [pii]
LID - 10.1016/j.peptides.2013.03.004 [doi]
AB  - Ghrelin, an acylated peptide produced in the stomach, increases food intake and 
      growth hormone secretion, inhibits pro-inflammatory cascade, etc. Ghrelin and its 
      receptor (GHS-R1a) mRNA were found in the area related to the regions for 
      controlling pain transmission, such as the hypothalamus, the midbrain, the spinal 
      cord, etc. Ghrelin has been shown to have antinociceptive activity and also 
      anti-inflammatory properties in inflammatory pain and chronic neuropathic pain. 
      Therefore, the aim of the present study was to investigate the effects of ghrelin 
      for the first time in the acute pain modulation at the supraspinal level, using 
      the tail withdrawal test and hot-plate test in mice. Intracerebroventricular 
      (i.c.v.) administration of ghrelin (mouse, 0.1-3 nmol) produced a dose- and 
      time-related antinociceptive effect in the tail withdrawal test and hot-plate 
      test, respectively. Antinociceptive effect elicited by ghrelin (i.c.v., 1 nmol) 
      was significantly antagonized by opioid receptor antagonist naloxone (i.c.v., 10 
      nmol co-injection or i.p., 10mg/kg, 10 min prior to ghrelin) in both tail 
      withdrawal test and hot-plate test. At these doses, naloxone significantly 
      antagonized the antinociceptive effect induced by morphine (i.c.v., 3 nmol). 
      Ghrelin (i.c.v., 1 nmol)-induced antinociception was significantly antagonized by 
      co-injection with 10 nmol [d-Lys3]-GHRP-6, the selective antagonist of GHS-R1a 
      identified more recently, while [d-Lys3]-GHRP-6 (10 nmol) alone induced neither 
      hyperalgesia nor antinociception. Overall this data indicate that ghrelin could 
      produce antinociception through an interaction with GHS-R1a and with the central 
      opioid system. Thus ghrelin may be a promising peptide for developing new 
      analgesic drugs.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Wei, Jie
AU  - Wei J
AD  - Department of Physiology, Medical College of Nanchang University, Bayi Road 461, 
      Nanchang, Jiangxi 330006, China. jwei@ncu.edu.cn
FAU - Zhi, Xing
AU  - Zhi X
FAU - Wang, Xiao-Lang
AU  - Wang XL
FAU - Zeng, Ping
AU  - Zeng P
FAU - Zou, Ting
AU  - Zou T
FAU - Yang, Bei
AU  - Yang B
FAU - Wang, Jing-Lei
AU  - Wang JL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130314
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Ghrelin)
SB  - IM
MH  - Acute Pain/*drug therapy
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Ghrelin/administration & dosage/*pharmacology/*therapeutic use
MH  - Injections, Intraventricular
MH  - Mice
MH  - Mice, Inbred Strains
MH  - Spinal Cord/*drug effects/pathology
EDAT- 2013/03/19 06:00
MHDA- 2014/08/20 06:00
CRDT- 2013/03/19 06:00
PHST- 2013/02/04 00:00 [received]
PHST- 2013/03/04 00:00 [revised]
PHST- 2013/03/04 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2014/08/20 06:00 [medline]
AID - S0196-9781(13)00078-8 [pii]
AID - 10.1016/j.peptides.2013.03.004 [doi]
PST - ppublish
SO  - Peptides. 2013 May;43:76-82. doi: 10.1016/j.peptides.2013.03.004. Epub 2013 Mar 
      14.